Acquisition Announced

Aurinia Pharmaceuticals acquisition of Kezar Life Sciences

US$51.5m equity value

Announced 30 Mar 2026 · NASDAQ: KZR · US$6.96 per share

Advisers

Kezar Life Sciences

Target

Financial adviser
TD Securities (as TD Cowen)
Legal adviser
Fairness opinion
TD Securities (as TD Cowen)

Aurinia Pharmaceuticals

Acquirer

Not disclosed

Target
Kezar Life Sciences
Acquirer
Aurinia Pharmaceuticals
Target based in
United States
Buyer based in
Canada
Sector
Biotech
Tags
Biotech, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.